Search Results

Lakewood-Amedex Inc. announced that Sumita Paul, MD, MPH, MBA has joined Lakewood-Amedex as Chief Medical Officer and Senior Vice President, Research and Development to lead its recently recruited scientific-clinical management team.

Lakewood-Amedex, Inc. announced today that it has commenced its second Phase 2 study using Bisphosphocin Nu-3 antimicrobial in treating patients with diabetic foot ulcers (DFU).

Elects Thomas Pfisterer and Douglas Manion, MD, FRCP(C), to the Board of Directors.

Transparency Life Sciences (TLS) today announced a partnership with the Lakewood Amedex Inc. for crowdsourced design of a Phase 2a/b protocol to test a novel class of synthetic broad-spectrum antimicrobials and antifungals for the treatment of Chronic Diabetic Foot Ulcers (cDFU).

Lakewood-Amedex Inc. announced that the U.S. Patent and Trademark Office has issued a “Notice of Allowance” for two broad patent applications related to the Company’s broad-spectrum antimicrobial Nu-8 Bisphosphocin compound, titled “Antimicrobial Compounds, Compositions, and Uses Thereof.” The “Notice of Allowance” indicates that the USPTO is satisfied that the patent applications meet all USPTO requirements.

Lakewood-Amedex Inc., a leading developer of novel anti-infective pharmaceuticals, announced today it had entered into a collaboration agreement with Nassau based Foot and Ankle International (Bahamas) to conduct two Phase 2 cDFU clinical trial for its topically applied Nu-3 antimicrobial used to eliminate infection and promote wound healing in patients with chronic diabetic foot ulcers (cDFU).